Clinical Trial Update: Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05) [Phase 2, Phase 3]

View source ↗

Summary

Completed Phase 2/3 trial in Japanese adults aged 20-70 with bronchial asthma evaluating the efficacy and safety of roflumilast.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchial Asthma

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Bronchial Asthma | Phase 2, Phase 3 | Status: COMPLETED